Mizuho Financial Stock Forum

Mizuho Americas' loan to Grameen America is a positive move for financial inclusion and support for low-income entrepreneurial women. This strengthens their partnership and promotes social and economic change for women entrepreneurs in underserved communities.

Magellan's chairman, Andrew Formica, sees the U.S. market as a major growth opportunity and anticipates it to drive future growth. The company's H1 results were positively received, with stock up 4.3%.

The appointment of Featherston, who is recognized as a proven leader with a successful track record, is expected to positively impact and drive growth in Mizuho Americas by offering differentiated content and improved people management.

Meanwhile, it looks like Intel is finally getting some love on Wall Street. Mizuho Securities analyst Vijay Rakesh upgraded Intel stock from “neutral” to “buy” and raised his price target on the shares from $37 to $50.
Rakesh now sees Intel as being “refocused on a better 2024 estimated” data center and personal computer “road map.” This could drive Intel’s turnaround story after the company lost market share in these segments and, Rakesh posits, help improve I...

Concerns arise from analysts over Robinhood's potential growth due to expected weakened volumes and challenging revenue conditions. However, some like Mizuho's Dan Dolev, remain long-term bullish, citing steady user activity and cost-control measures.

BTIG analysts predict declining sales to impact Toast's revenue, citing uncontrollable factors. Mizuho analysts flagged lower payment volume, downgrading the stock and reducing the price target. Meanwhile, William Blair retains an optimistic outlook despite macro headwinds.

Mizuho states that Merck has better diversified its revenue, lessening dependency on KEYTRUDA. Other candidates across multiple therapeutic areas may also contribute, relieving revenue pressure from KEYTRUDA's potential patent expiry and pricing pressures.